摘要
目的：探讨齐拉西酮与利培酮对精神分裂症伴抑郁症状患者的临床疗效以及代谢功能的影响。方法将80例精神分裂症伴抑郁症状患者按随机数字表法分为两组，每组40例，观察组口服齐拉西酮治疗，对照组口服利培酮治疗，观察2个月。治疗前后采用阳性与阴性症状量表评定临床疗效，检测空腹血糖、胆固醇、血清泌乳素水平及体质量的变化。结果治疗后观察组总有效率为95．0％、对照组为90％，两组比较差异无显著性（χ2＝0．72，P＞0．05）。治疗后观察组空腹血糖、胆固醇、血清泌乳素水平及体质量与治疗前比较均无显著变化（P＞0．05）；对照组各项指标水平均较治疗前显著升高（P＜0．01），且显著高于观察组（P＜0．01）。结论齐拉西酮与利培酮治疗精神分裂症伴抑郁症状患者疗效显著，但齐拉西酮对患者代谢功能影响较小，更有利于提高患者的治疗依从性。
Objective To explore the influences of ziprasidone and risperidone on the curative effects and metabolism of schizophrenics complicated by depression .Methods Eighty schizophrenics complicated by depression were randomly assigned to two groups of 40 ones each ,observation group took orally ziprasi‐done and control group did risperidone for 2 months .Efficacies were assessed with the Positive and Nega‐tive Syndrome Scale （TESS） before and after treatment and changes of fasting blood glucose （FBG） ,cho‐lesterol and serum lactotropin levels as well as body mass .Results After treatment the total effective rate was respectively 95 .0% in observation and 90% in control groups ,which showed no significant group difference （χ2 =0 .72 ,P〉 0 .05） .There were no significant differences between pre‐and post‐treatment FBG ,cholesterol and serum lactotropin levels as well as body mass （ P〉 0 .05）;all indexes heightened more significantly after treatment compared with pretreatment in observation group （P〈0 .01） and were significantly higher than those in control group （P〈0 .01） .Conclusion Both ziprasidone and risperidone are significantly effective in schizophrenia complicated by depression ,but ziprasidone has less influence on metabolism and is beneficial to boost patients’ treatment compliance .
出处
《临床心身疾病杂志》
CAS
2016年第4期23-25,共3页
Journal of Clinical Psychosomatic Diseases
作者简介
蔡丽莉，女，35岁，汉族，本科，主治医师。研究方向：精神疾病诊治。
